Exact Sciences Corp., one of the world’s foremost innovators in cancer screening, diagnostics, and precision oncology solutions, has announced that it will present a robust collection of ten scientific abstracts at the upcoming 2025 San Antonio Breast Cancer Symposium (SABCS). Scheduled to be held from December 9–12 in San Antonio, Texas, SABCS remains one of the most influential global stages for emerging breast cancer research, and Exact Sciences’ substantial participation underscores its enduring commitment to advancing evidence-based, patient-centered cancer care.
The company’s contributions this year span its entire Precision Oncology portfolio, reflecting years of investment in molecular science, clinical validation, and the development of tools that support more personalized and equitable treatment for patients around the world. SABCS attendees will gain insights into new data across multiple areas of breast cancer diagnosis, prognosis, recurrence prediction, and ongoing surveillance—each representing a key component of the modern cancer care continuum.
Central to Exact Sciences’ presence at the 2025 symposium is its continuing work to strengthen the clinical foundation of Oncotype DX®, the company’s widely adopted genomic test designed to guide therapy decisions for patients with early-stage breast cancer. Oncotype DX has become internationally recognized as a benchmark tool for predicting the likelihood of chemotherapy benefit and estimating the risk of distant recurrence. Its role in tailoring treatment recommendations has been instrumental in minimizing overtreatment, reducing toxicity, improving long-term outcomes, and helping clinicians practice truly personalized medicine.
For more than two decades, Oncotype DX has been backed by an extensive library of independent studies, real-world evidence, and validation across diverse populations. This longstanding commitment to rigorous science reinforces the test’s reliability and global relevance. At the 2025 SABCS, Exact Sciences aims to demonstrate how its continued research helps expand clinical utility, improve confidence in treatment planning, and support practice-changing decision-making in oncology.
Beyond Oncotype DX, the company’s presentations this year will highlight important new findings related to Oncodetect™, Exact Sciences’ molecular residual disease (MRD) test. MRD testing has emerged as one of the most promising frontiers in oncology, offering a sensitive way to detect microscopic traces of cancer that remain after initial treatment—long before they are visible on imaging or through traditional diagnostic methods. Early identification of residual disease has the potential to reshape how high-risk patients are monitored, allowing clinicians to detect recurrence sooner and tailor follow-up strategies more precisely.
“Oncotype DX has long set a global standard as a predictive and prognostic test in breast cancer, helping clinicians confidently guide therapy decisions that improve outcomes and reduce disparities,” said Dr. Rick Baehner, Chief Medical Officer, Precision Oncology, Exact Sciences. “The data presented at this year’s SABCS reaffirms our leadership in breast cancer prediction and prognosis and expands our evidence base for Oncodetect—our molecular residual disease test—as a powerful recurrence predictor and tool for personalizing surveillance in high-risk patients.”
Dr. Baehner’s remarks capture the central theme of Exact Sciences’ approach: pairing innovation with scientific rigor and ensuring that emerging technologies truly serve the needs of patients across diverse clinical settings. The company’s goal extends beyond developing advanced diagnostic tools—it is equally committed to ensuring that these technologies are accurate, accessible, and capable of supporting equitable care, particularly in populations that have historically been underserved or underrepresented in cancer research.
SABCS 2025 provides an ideal platform for presenting evidence that strengthens this mission. Across the ten abstracts, researchers from Exact Sciences and collaborating institutions will share new insights on a range of clinically relevant topics, including:
- Updated performance data for Oncotype DX in different breast cancer subtypes, helping refine how clinicians interpret results for complex or borderline cases.
- Real-world evidence examining treatment decisions influenced by Oncotype DX scores, further clarifying how the test impacts clinical practice patterns worldwide.
- Expanded validation of Oncodetect’s ability to identify molecular residual disease, potentially reshaping early detection of recurrence in patients with high-risk or aggressive breast cancer.
- Studies assessing MRD-guided surveillance strategies, which may help personalize follow-up intensity and improve patient quality of life.
- Research exploring disparities in diagnostic access and outcomes, supporting Exact Sciences’ emphasis on improving equity in breast cancer care.
- New analytical performance metrics demonstrating assay sensitivity and robustness, underscoring the scientific quality of the Precision Oncology portfolio.
The breadth of research reflects the company’s understanding that breast cancer care is not defined by a single clinical moment. Instead, it is a journey requiring early detection, precise diagnosis, individualized treatment guidance, and vigilant long-term monitoring. By focusing on every stage—from initial testing to survivorship—Exact Sciences aims to offer clinicians a unified toolbox that helps them deliver the best possible outcomes for their patients.
Another key theme underlying Exact Sciences’ SABCS participation is the role of genomics and molecular insights in shaping the future of oncology. As the field evolves, clinicians increasingly rely on tests that provide actionable information rather than broad categorizations. Whether determining the necessity of chemotherapy, predicting the risk of recurrence, or identifying residual disease after treatment, such focused molecular tools enable more precise care while reducing unnecessary interventions.
Exact Sciences’ investments in MRD science, for example, reflect growing recognition that cancer recurrence often begins at a microscopic level that conventional imaging cannot detect. By identifying molecular signals earlier, clinicians may intervene sooner or modify surveillance plans to better support patient outcomes. The new data presented at SABCS further validates this approach and highlights Oncodetect as a compelling addition to the suite of tools used to manage long-term breast cancer risk.
Furthermore, the company’s commitment to equitable care is reflected not only in its research but also in its broader initiatives. Exact Sciences continues to support studies that evaluate test performance across various demographic groups, including populations that have traditionally been underrepresented in clinical trials. This ensures that precision oncology tools are genuinely applicable to all patients—not just those who fit a narrow clinical profile.
As SABCS remains one of the most respected platforms for unveiling groundbreaking advancements in breast cancer science, Exact Sciences’ extensive involvement signals both leadership and accountability within the global oncology community. The company’s strong presence this year underscores its dedication to building a future where breast cancer care is deeply personalized, scientifically grounded, and accessible to patients everywhere.
In summary, Exact Sciences’ presentation of ten abstracts at the 2025 San Antonio Breast Cancer Symposium represents more than a showcase of new data—it is a reaffirmation of the company’s vision for the future of precision oncology. Through continuous research, strategic innovation, and a persistent focus on patient needs, Exact Sciences is shaping a world where breast cancer detection, treatment, and long-term monitoring become more accurate, more individualized, and more equitable for all.
